Monopoly

BioInvent receives notice of allowance in China for BI-1206 patent

Retrieved on: 
Thursday, June 24, 2021

This patent allowance is a strategic milestone in BioInvent's exclusive licensing agreement with CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company with an established clinical development and commercial infrastructure in China.

Key Points: 
  • This patent allowance is a strategic milestone in BioInvent's exclusive licensing agreement with CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company with an established clinical development and commercial infrastructure in China.
  • In 2020, CASI gained the rights for the development and commercialization of BI-1206 in mainland China, Taiwan, Hong Kong, and Macau.
  • Other patents in the same patent family have already been granted by the European Patent Office and in several other countries, including the US and Japan.
  • The company also has related patent applications pending in some countries.

BioInvent receives notice of allowance in China for BI-1206 patent

Retrieved on: 
Thursday, June 24, 2021

This patent allowance is a strategic milestone in BioInvent's exclusive licensing agreement with CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company with an established clinical development and commercial infrastructure in China.

Key Points: 
  • This patent allowance is a strategic milestone in BioInvent's exclusive licensing agreement with CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company with an established clinical development and commercial infrastructure in China.
  • In 2020, CASI gained the rights for the development and commercialization of BI-1206 in mainland China, Taiwan, Hong Kong, and Macau.
  • Other patents in the same patent family have already been granted by the European Patent Office and in several other countries, including the US and Japan.
  • The company also has related patent applications pending in some countries.

First American Financial Corporation Appoints Rouz Tabaddor Chief Intellectual Property Officer

Retrieved on: 
Wednesday, June 23, 2021

First American Financial Corporation (NYSE: FAF), a leading provider of title insurance, settlement services and risk solutions for real estate transactions, today announced the appointment of Rouz Tabaddor as vice president and chief intellectual property officer, a new position that will accelerate the expansion and monetization of the companys intellectual property portfolio, which already includes 30 active patents and an additional 13 patent applications pending.

Key Points: 
  • First American Financial Corporation (NYSE: FAF), a leading provider of title insurance, settlement services and risk solutions for real estate transactions, today announced the appointment of Rouz Tabaddor as vice president and chief intellectual property officer, a new position that will accelerate the expansion and monetization of the companys intellectual property portfolio, which already includes 30 active patents and an additional 13 patent applications pending.
  • Tabaddor will be responsible for the identification, protection and enforcement of the companys intellectual property assets with an emphasis on furthering First Americans leadership in driving innovation.
  • Rouz is a proven leader in expanding and protecting intellectual property portfolios and has an impressive record in defending and enforcing intellectual property rights, said Ken DeGiorgio, president of First American Financial Corporation.
  • Tabaddor joins First American with more than 20 years experience practicing law with an emphasis on intellectual property, litigation, privacy, licensing, and audit and enforcement.

In NCLA Amicus Win, Supreme Court Rules Admin. Patent Judges Are Unconstitutionally Appointed

Retrieved on: 
Monday, June 21, 2021

APJs had previously been appointed by the U.S. Secretary of Commerce in violation of the Appointments Clause of the U.S. Constitution.

Key Points: 
  • APJs had previously been appointed by the U.S. Secretary of Commerce in violation of the Appointments Clause of the U.S. Constitution.
  • Smith & Nephew, Inc. challenged the validity of a patent held by Arthrex, Inc. A three-APJ panel held that the challenged claims of the patent were invalid.
  • The Court held that APJs were not appointed to their positions in the manner Article II of the Constitution requires.
  • NCLA is pleased that the Court has taken another step toward making executive officials more accountable to the President and the people.

Activist Supreme Court Sides with Big Tech on Patent Invalidation Board

Retrieved on: 
Tuesday, June 22, 2021

The Court then proceeded to "forgive" this violation by re-writing the law.

Key Points: 
  • The Court then proceeded to "forgive" this violation by re-writing the law.
  • Malone said it is impossible for the Director to review the thousands of decisions that rob inventors of our hard-earned rights.
  • Certainly, it will not be under-resourced inventors who benefit under this holding, but rather the wealthiest and most politically connected corporations.
  • "Today's decision marks another in a string of decisions by the U.S. Supreme Court that has flipped our patent system upside down.

AnPac Bio’s First Disease Treatment Patent Granted, and Its Cancer Treatment Project Secured Multi-Million Dollar Funds

This latest patent is the twenty first patent granted to AnPac Bio in the United States.

Key Points: 
  • This latest patent is the twenty first patent granted to AnPac Bio in the United States.
  • We are pleased that AnPac Bio has been granted our first disease treatment patent, whose disease treatment related claims will be licensed to our new cancer treatment joint venture (while future disease treatment only patent applications will be transferred to the cancer treatment joint venture).
  • We are also pleased that our cancer treatment joint venture has secured funding to speed up its cancer treatment developments.
  • AnPac Bio is a biotechnology company focused on early cancer screening and detection as well as cancer treatment, with 142 issued patents as of March 31, 2021.

Entera Bio Receives Foundational Patent for its Oral PTH using its Platform Oral Protein Delivery Technology in European Union

Retrieved on: 
Thursday, June 17, 2021

The patent addresses Enteras oral PTH formulations currently in advanced clinical stages for osteoporosis and hypoparathyroidism.

Key Points: 
  • The patent addresses Enteras oral PTH formulations currently in advanced clinical stages for osteoporosis and hypoparathyroidism.
  • This is a critical patent that covers lead PTH products utilizing Enteras platform technology.
  • This European Union patent, along with a variety of other patents covering oral formulations and target indications, granted and pending, provide Entera with robust protection of its intellectual property.
  • Entera cautions investors not to rely too heavily on the forward-looking statements Entera makes or that are made on its behalf.

Nano One Granted 3 New Patents

Retrieved on: 
Thursday, June 17, 2021

Vancouver, British Columbia--(Newsfile Corp. - June 17, 2021) - Nano One Materials Corp. (TSX: NANO) (OTC PINK: NNOMF) (FSE: LBMB) ( Nano One ) is a clean technology company with a patented process for the low-cost, low-carbon footprint production of high-performance cathode materials used in lithium-ion batteries.

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - June 17, 2021) - Nano One Materials Corp. (TSX: NANO) (OTC PINK: NNOMF) (FSE: LBMB) ( Nano One ) is a clean technology company with a patented process for the low-cost, low-carbon footprint production of high-performance cathode materials used in lithium-ion batteries.
  • Nano One today announced that its patent estate will expand to include three (3) issued patents, bringing Nano One's patents to a total of 19 with more than 35 patent applications pending.
  • This patent will extend the protection related to specific components of the proprietary One-Pot process developed by Nano One.
  • The recently issued Chinese Patent 2017100669194 joins a family of related patents already issued in the US, Canada, Taiwan, Japan and Korea.

WISeKey’s TrustedNFT Platform to Turn Patents into Non-Fungible Tokens (NFT) and Store Them on an Identity Blockchain Network

Retrieved on: 
Tuesday, June 15, 2021

WISeKey is inviting companies and individuals holding patents to join its NFT patent ecosystem powered by the extensive list of patents owned by the company for more information visit: https://www.wisekey.com/company/our-value-proposition/our-patents/ .

Key Points: 
  • WISeKey is inviting companies and individuals holding patents to join its NFT patent ecosystem powered by the extensive list of patents owned by the company for more information visit: https://www.wisekey.com/company/our-value-proposition/our-patents/ .
  • With a rich portfolio of more than 46 patent families, covering over 100 fundamental individual patents, and another 22 patents under review, WISeKey continues to expand its TrustedNFT platform use in various domains.
  • WISeKeys patented technology that already secures millions of objects (luxury products, expensive wine, jewelry, collectors items, high end watches, art, etc.
  • The platform generates patents related smart contracts acting as a program that runs on the blockchain that they can receive and send transactions, and they are unalterable.

Top 100 Worldwide Universities Granted U.S. Utility Patents in 2020 Announced

Retrieved on: 
Tuesday, June 15, 2021

TAMPA, Fla., June 15, 2021 /PRNewswire/ -- The Top 100 Worldwide Universities Granted U.S. Utility Patents in 2020 report was released today by the National Academy of Inventors (NAI) and the Intellectual Property Owners Association (IPO).

Key Points: 
  • TAMPA, Fla., June 15, 2021 /PRNewswire/ -- The Top 100 Worldwide Universities Granted U.S. Utility Patents in 2020 report was released today by the National Academy of Inventors (NAI) and the Intellectual Property Owners Association (IPO).
  • Published annually since 2013, the report ranks the top 100 universities named as first assignee on utility patents granted by the USPTO in the 2020 calendar year.
  • The IPO Top 300 Patent Owners List, published annually since 1985, ranks organizations worldwide that received the most U.S. utility patents during the previous calendar year.
  • It lists the total number of patents for 2020's Top 100 universities (including U.S. and international universities) to be 7,734.